Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2018 Apr 12



Publication history
Per citare questo articolo


Rivista di Medicina Interna

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878



Minerva Medica 2018 Apr 12

DOI: 10.23736/S0026-4806.18.05628-8


lingua: Inglese

Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease (PAD)

Peter JIRAK 1, Moritz MIRNA 1, Bernhard WERNLY 1, Vera PAAR 1, Marcus THIEME 2, Stefan BETGE 2, Marcus FRANZ 2, Uta HOPPE 1, Alexander LAUTEN 3, 4, Jürgen KAMMLER 5, Paul C. SCHULZE 2, Michael LICHTENAUER 1 , Daniel KRETZSCHMAR 2

1 Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria; 2 Universitätsherzzentrum Thüringen, Clinic of Internal Medicine I, Department of Cardiology, Friedrich Schiller University Jena, Jena, Germany; 3 Department of Cardiology, Charité, Universitaetsmedizin Berlin, Berlin, Germany; 4 Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Standort Berlin, Berlin, Deutschland; 5 Department of Cardiology, Kepler University Hospital Linz, Linz, Austria


BACKGROUND: Peripheral artery disease (PAD) is a common form of manifestation of atherosclerosis. PAD has a considerable impact on morbidity, hospitalisation rates and health- care costs. Biomarkers have been introduced in many cardiovascular disease entities over the last years. However, an analysis on the correlation of biomarker levels and PAD is still lacking.
METHODS: A total of 106 patients were enrolled in this current study, 51 that were diagnosed with PAD and 55 with excluded coronary and peripheral artery disease as controls. During outpatient visits, plasma samples of all patients were obtained and analyzed for sST2 (hemodynamics and inflammation), Galectin-3 (fibrosis and remodeling), GDF-15 (remodeling and inflammation), suPAR (inflammation), and Fetuin-A (vascular calcification) by use of ELISA after informed consent.
RESULTS: Compared with controls, patients with PAD showed significantly higher levels of sST2 (5248 vs. 7503 pg/ml, p<0.001), suPAR (2267 vs. 2414 pg/ml, p=0.02), Galectin-3 (2795 vs. 4494 pg/ml, p<0.001), and GDF-15 (549 vs. 767 pg/ml, p<0.001). Fetuin-A showed a trend towards lower levels in patients with PAD (117 vs. 100 ng/ml, p=0.119).
CONCLUSIONS: Circulating levels of sST2, suPAR, Galectin-3, and GDF-15 were significantly elevated in PAD patients. In contrast, Fetuin-A levels showed a decrease in PAD patients indicating increased vascular calcification. Thus, by incorporating different pathophysiological processes present in PAD, tested novel biomarkers facilitate a more precise diagnosis as well as a more accurate evaluation of disease severity and progression.

KEY WORDS: Peripheral artery disease - Atherosclerosis - Inflammation - Biomarkers - sST2

inizio pagina

Publication History

Article first published online: April 12, 2018
Manuscript accepted: April 4, 2018
Manuscript received: March 24, 2018

Per citare questo articolo

Jirak P, Mirna M, Wernly B, Paar V, Thieme M, Betge S et al. Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease (PAD). Minerva Med 2018 Apr 12. DOI: 10.23736/S0026-4806.18.05628-8

Corresponding author e-mail